- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01183858
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
A Prospective, Double-blind Randomized Phase III Study of 300 mg Versus 150 mg Erlotinib in Current Smokers With Locally Advanced or Metastatic NSCLC in Second-line Setting After Failure on Chemotherapy (CURRENTS)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Hillerod, Danmark, 3400
-
København, Danmark, 2100
-
Naestved, Danmark, 4700
-
Roskilde, Danmark, 4000
-
-
-
-
-
Cairo, Egypten, 11796
-
Cairo, Egypten
-
-
-
-
-
Caen, Frankrike, 14076
-
Limoges, Frankrike, 87042
-
Marseille, Frankrike, 13915
-
Paris, Frankrike, 75014
-
Paris, Frankrike, 75908
-
Paris, Frankrike, 75674
-
Pontoise, Frankrike, 95300
-
-
-
-
-
Ankara, Kalkon, 06200
-
Ankara, Kalkon, 06000
-
Eskisehir, Kalkon, 26480
-
Gaziantep, Kalkon, 27310
-
Izmir, Kalkon, 35340
-
Izmir, Kalkon, 35110
-
Konya, Kalkon, 42050
-
-
-
-
-
Beijing, Kina, 100071
-
Changchun, Kina, 130012
-
Chengdu, Kina, 610041
-
Fuzhou, Kina, 350014
-
Guangzhou, Kina, 510030
-
Nanjing, Kina, 210009
-
Nanning, Kina, 530021
-
Shanghai, Kina, 200433
-
Shanghai, Kina, 200030
-
Shenyang, Kina, 110001
-
Tianjin, Kina, 300060
-
Wuhan, Kina, 430030
-
-
-
-
-
Amsterdam, Nederländerna, 1007 MB
-
Breda, Nederländerna, 4818 CK
-
Nieuwegein, Nederländerna, 3435 CM
-
Zwolle, Nederländerna, 8011 JW
-
-
-
-
-
Baden, Schweiz, 5404
-
Basel, Schweiz, 4031
-
Bern, Schweiz, 3011
-
Fribourg, Schweiz, 1708
-
-
-
-
-
Barcelona, Spanien, 08035
-
Barcelona, Spanien, 08041
-
Madrid, Spanien, 28040
-
Madrid, Spanien, 28041
-
Malaga, Spanien, 29010
-
Sevilla, Spanien, 41013
-
Valencia, Spanien, 46009
-
-
Barcelona
-
Sabadell, Barcelona, Barcelona, Spanien, 08208
-
-
-
-
-
Berlin, Tyskland, 13125
-
Berlin, Tyskland, 14165
-
Essen, Tyskland, 45122
-
Gauting, Tyskland, 82131
-
Grosshansdorf, Tyskland, 22927
-
Hannover, Tyskland, 30625
-
Hannover, Tyskland, 30659
-
Immenhausen, Tyskland, 34376
-
Lostau, Tyskland, 39291
-
München, Tyskland, 81925
-
Nürnberg, Tyskland, 90419
-
Rheine, Tyskland, 48431
-
Villingen-Schwenningen, Tyskland, 78052
-
Wuerselen, Tyskland, 52146
-
Wuppertal, Tyskland, 42283
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adult patients aged ≥18 years
- inoperable, locally advanced (stage IIIB/IV) with supraclavicular lymph node metastases or malignant pleural or pericardial effusion) or metastatic (stage IV) non-small cell lung cancer (NSCLC)
- Disease must be characterized according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
- Patients have received one prior platinum-based chemotherapy regimen for advanced NSCLC, but must have recovered from any treatment-related toxicity
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Life expectancy ≥12 weeks
- Current cigarette smoker (having smoked >100 cigarettes in entire lifetime and currently smoking on average ≥1 cigarette per day), not intending to stop during the study
Exclusion Criteria:
- Prior antibody or small molecule therapy against Epidermal growth factor receptor (EGFR)
- Radiotherapy within 28 days prior to enrollment
- Received more than one line of chemotherapy for locally advanced/metastatic NSCLC (first-line maintenance chemotherapy after first-line platinum-based chemotherapy is allowed)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Erlotinib 150 mg
Erlotinib 150 mg single daily oral dose until disease progression.
|
Single daily oral dose
Andra namn:
|
Experimentell: Erlotinib 300 mg
Erlotinib 300 mg single daily oral dose until disease progression.
|
Single daily oral dose
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Progression-Free Survival (PFS)
Tidsram: Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 Months)
|
PFS is defined as the time from randomization to the date of first occurrence of disease progression or death.
For target lesions, Progressive Disease (PD) was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions.
For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.
|
Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 Months)
|
Progression-Free Survival (PFS) at the End of Study
Tidsram: Randomization to End of Study: 14 October 2010 - 7 February 2014 (Up to 39.8 months)
|
PFS is defined as the time from randomization to the date of first occurrence of disease progression or death.
For target lesions, Progressive Disease (PD) was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions.
For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.
|
Randomization to End of Study: 14 October 2010 - 7 February 2014 (Up to 39.8 months)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Overall Survival (OS)
Tidsram: Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 months)
|
OS defined as the time from randomization to the date of death due to any cause.
|
Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 months)
|
Overall Response Rate (ORR)
Tidsram: Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 months)
|
Tumor response was assessed by the investigator using computer tomography (CT) or magnetic resonance imaging (MRI) scans according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
A participant was defined as a responder if they sustained a complete response (CR) or partial response (PR) for at least 4 weeks during randomized treatment (confirmed response).
Patients with no tumor assessment after the start of study treatment were to be considered as non-responders.
The percentage of participants in each best response category is presented.
|
Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 months)
|
Disease Control Rate (DCR)
Tidsram: Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 months)
|
Tumor response was assessed by the investigator using computer tomography (CT) or magnetic resonance imaging (MRI) scans.
Disease control rates were measured according to RECIST version 1.1 criteria.
A participant was defined as having controlled disease if they sustained a Complete Response (CR) or Partial Response (PR) for at least 4 weeks during randomized treatment (confirmed response), or Stable Disease (SD) for at least 6 weeks.
Patients with no tumor assessment after the start of study treatment were considered as having uncontrolled disease.
The percentage of participants with Disease Control is presented.
|
Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 months)
|
Time to Progression (TTP)
Tidsram: Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 months)
|
Tumor response was assessed by the investigator using computer tomography (CT) or magnetic resonance imaging (MRI) scans according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
Time to progression (TTP) in weeks was defined as the time from randomization to the date of disease progression.
Participants without event were censored at the date of the last tumor assessment when the patient was known to be progression free.
|
Randomization to Clinical Cutoff: 28 October 2013 (Up to 36.5 months)
|
Number of Participants With Adverse Events (AEs) at the End of the Study
Tidsram: Randomization to End of Study: 14 October 2010 - 7 February 2014 (Up to 39.8 months)
|
An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. Adverse Events in the following categories are presented: Adverse Events, Serious Adverse Events, AEs leading to withdrawal from treatment and AEs leading to death. |
Randomization to End of Study: 14 October 2010 - 7 February 2014 (Up to 39.8 months)
|
Overall Survival (OS) at the End of Study
Tidsram: Randomization to End of Study: 14 October 2010 - 7 February 2014 (Up to 39.8 months)
|
OS defined as the time from randomization to the date of death due to any cause.
|
Randomization to End of Study: 14 October 2010 - 7 February 2014 (Up to 39.8 months)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Neoplasmer
- Lungsjukdomar
- Neoplasmer efter plats
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Karcinom, bronkogent
- Bronkiella neoplasmer
- Lungneoplasmer
- Karcinom, icke-småcellig lunga
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Proteinkinashämmare
- Erlotinib hydroklorid
Andra studie-ID-nummer
- MO22162
- 2010-018476-24 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Icke-småcellig lungcancer
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeRefraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Mogen T-cell och NK-cell non-Hodgkin lymfom | Återkommande moget T- och NK-cells non-Hodgkin-lymfom | Återkommande kutant T-cell non-Hodgkin lymfom | Refraktärt kutant T-cell non-Hodgkin lymfomFörenta staterna
-
National Cancer Institute (NCI)AvslutadÅterkommande kutant T-cell non-Hodgkin lymfom | Steg I Kutant T-cell non-Hodgkin lymfom | Steg II Kutant T-cell non-Hodgkin lymfomFörenta staterna
-
Stanford UniversityNational Institutes of Health (NIH); AmgenAvslutadLymfom, icke-Hodgkin | Lymfom: Non-Hodgkin | Lymfom: Icke-Hodgkin perifer T-cell | Lymfom: Non-Hodgkin kutant lymfom | Lymfom: Non-Hodgkin Diffus Stor B-cell | Lymfom: Non-Hodgkin follikulära / indolenta B-cell | Lymfom: Non-Hodgkin Mantle Cell | Lymfom: Non-Hodgkin Marginal Zone | Lymfom: Non-Hodgkin...Förenta staterna
-
Novartis PharmaceuticalsAvslutadMelanom | Trippel negativ bröstcancer | Anaplastisk sköldkörtelcancer | Andra fasta tumörer | Non-small Sell Lung Cancer (NSCLC)Förenta staterna, Italien, Spanien, Ungern, Taiwan, Tyskland, Nederländerna, Frankrike, Norge, Polen, Thailand, Libanon, Kalkon, Kanada
-
John ReneauAktiv, inte rekryterandeÅterkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Steg III kutant T-cell non-Hodgkin lymfom | Steg IV Kutant T-cell non-Hodgkin lymfom | Primärt kutant anaplastiskt storcelligt lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom | Lymfomatoid... och andra villkorFörenta staterna
-
City of Hope Medical CenterNational Cancer Institute (NCI)AvslutadAnaplastiskt storcelligt lymfom | Återkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfomFörenta staterna
-
Walter HanelRekryteringÅterkommande mogna T-cell och NK-cell non-Hodgkin lymfom | Återkommande primärt kutant T-cells non-Hodgkin-lymfom | Refraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Refraktärt anaplastiskt storcelligt lymfom | T-cell non-Hodgkin lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom och andra villkorFörenta staterna
-
National Cancer Institute (NCI)RekryteringRefraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande transformerat non-Hodgkin-lymfom | Återkommande non-Hodgkin lymfom | Refraktärt non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfom | Återkommande primärt kutant... och andra villkorFörenta staterna
-
Mayo ClinicHar inte rekryterat ännuIndolent B-cell non-Hodgkin lymfom | Återkommande indolent non-Hodgkin-lymfom | Refraktärt indolent non-Hodgkin-lymfom | Återkommande indolent B-cell non-Hodgkin lymfom | Refraktärt indolent B-cell non-Hodgkin lymfomFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadÅterkommande Hodgkin-lymfom | Refraktärt Hodgkin-lymfom | Refraktärt B-cells non-Hodgkin-lymfom | Refraktärt T-cell non-Hodgkin lymfom | Återkommande B-cells non-Hodgkin lymfom | Återkommande T-cell non-Hodgkin lymfomFörenta staterna
Kliniska prövningar på Erlotinib [Tarceva]
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern... och andra samarbetspartnersAvslutad
-
PfizerAvslutadKarcinom, icke-småcellig lungaFörenta staterna
-
M.D. Anderson Cancer CenterAvslutadAvancerad cancerFörenta staterna
-
Merck Sharp & Dohme LLCAvslutad
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Genentech, Inc.AvslutadKarcinom, icke-småcellig lungaFörenta staterna
-
PharmaMarAvslutadAvancerade maligna solida tumörerSpanien, Förenta staterna
-
Tragara Pharmaceuticals, Inc.AvslutadÅterkommande icke småcellig lungcancerFörenta staterna
-
PfizerAvslutadIcke-småcellig lungcancerFörenta staterna, Korea, Republiken av, Storbritannien, Grekland, Slovakien, Frankrike, Belgien, Irland, Japan, Spanien, Kina, Sverige, Indien, Ungern, Schweiz, Ryska Federationen, Tyskland, Mexiko, Danmark, Österrike, Finland, Polen, Sydafri...
-
New Mexico Cancer Care AllianceAvslutadAvancerade solida tumörmaligniteterFörenta staterna
-
SCRI Development Innovations, LLCBayerAvslutadIcke-småcellig lungcancerFörenta staterna